- Home
- MVSTW vs RLAY Comparison
MVSTW vs RLAY Comparison
Compare MVSTW & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVSTW | RLAY |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | 1921 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MVSTW | RLAY |
|---|---|---|
| Price | $0.13 | $8.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 126.0K | ★ 2.4M |
| Earning Date | 03-14-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $370,989,000.00 | $8,355,000.00 |
| Revenue This Year | N/A | $20.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.03 | N/A |
| 52 Week Low | $0.35 | $1.78 |
| 52 Week High | $0.44 | $9.04 |
Technical Indicators
Market Signals| Indicator | MVSTW | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 44.62 | 53.66 |
| Support Level | $0.07 | $7.66 |
| Resistance Level | $0.16 | $8.58 |
| Average True Range (ATR) | 0.04 | 0.44 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 60.32 | 44.78 |
Price Performance
Historical ComparisonAbout MVSTW Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).